Ibrutinib (Imbruvica) with rituximab for Waldenström's macroglobulinaemia – untreated or previously treated patients

NIHR HSRIC

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' conclusions
Ibrutinib is a new drug to treat Waldenström's macroglobulinaemia, which is a rare type of slow growing cancer called non-Hodgkin lymphoma. It develops when a type of white blood cells, called plasma cells, become abnormal and grow out of control. Ibrutinib is taken as a tablet in combination with a chemotherapy drug called rituximab. Some studies have suggested this combination may offer a useful additional treatment option for patients with Waldenström's macroglobulinaemia.

Final publication URL
http://www.hsric.nihr.ac.uk/topics/ibrutinib-imbruvica-with-rituximab-for-waldenstroems-macroglobulinaemia-untreated-or-previously-treated-patients/

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Pyrazoles; Pyrimidines; Rituximab; Waldenstrom Macroglobulinemia

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
NIHR Horizon Scanning Research & Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk

AccessionNumber
32016001028

Date abstract record published
11/10/2016